Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023

IF 4.1 2区医学 Q1 RHEUMATOLOGY

Arthritis Care & Research Pub Date : 2026-08-26 Epub Date: 2026-03-13 DOI:10.1002/acr.70042

Danielle Dawson MPH, Kurt J. Greenlund PhD, Kamil E. Barbour PhD

{"title":"Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years—United States, 2018–2023","authors":"Danielle Dawson MPH, Kurt J. Greenlund PhD, Kamil E. Barbour PhD","doi":"10.1002/acr.70042","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can lead to death. To examine SLE as an underlying and contributing cause of death, the Centers for Disease Control and Prevention (CDC) analyzed 2018 to 2023 mortality data for persons aged ≥15 years overall and by age, sex, race and ethnicity, and region.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Death certificate data for persons aged ≥15 years with any mention of SLE (<i>International Classification of Diseases, Tenth Revision</i> [ICD-10] code M32) were analyzed using the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) system. We calculated age-adjusted death rates and assessed patterns by sex, age, race and ethnicity, and region. Underlying and contributing causes of death were evaluated using ranked cause-of-death lists and ICD-10 subchapters.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During 2018 to 2023, 14,936 deaths had any mention of SLE listed on the death certificates. Of these deaths, 6,414 (42.9%) listed SLE as the underlying cause. The age-adjusted SLE mortality rate per million population was greater among females (5.97) than males (1.16), non-Hispanic African American persons (10.70) than persons of other non-Hispanic racial groups (range 2.46–5.62), Hispanic persons (3.98) than non-Hispanic persons (3.59), and people in the South (4.37) than people in other regions. When SLE was listed as a contributing cause of death, the leading underlying causes were heart disease (0.93), cancer (0.56), and COVID-19 (0.51). The overall age-adjusted SLE mortality rates were significantly higher in 2020 and 2021 than in all other study years, indicating the likely impact of the COVID-19 pandemic on SLE mortality.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Overall management of SLE, comorbidities, and infections in patients with SLE, as well as interventions targeting groups (eg, African American persons) disproportionately impacted by SLE, may reduce overall SLE mortality.</p>\n </section>\n </div>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"78 9","pages":"1188-1194"},"PeriodicalIF":4.1000,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Care & Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acr.70042","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can lead to death. To examine SLE as an underlying and contributing cause of death, the Centers for Disease Control and Prevention (CDC) analyzed 2018 to 2023 mortality data for persons aged ≥15 years overall and by age, sex, race and ethnicity, and region.

Methods

Death certificate data for persons aged ≥15 years with any mention of SLE (International Classification of Diseases, Tenth Revision [ICD-10] code M32) were analyzed using the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) system. We calculated age-adjusted death rates and assessed patterns by sex, age, race and ethnicity, and region. Underlying and contributing causes of death were evaluated using ranked cause-of-death lists and ICD-10 subchapters.

Results

During 2018 to 2023, 14,936 deaths had any mention of SLE listed on the death certificates. Of these deaths, 6,414 (42.9%) listed SLE as the underlying cause. The age-adjusted SLE mortality rate per million population was greater among females (5.97) than males (1.16), non-Hispanic African American persons (10.70) than persons of other non-Hispanic racial groups (range 2.46–5.62), Hispanic persons (3.98) than non-Hispanic persons (3.59), and people in the South (4.37) than people in other regions. When SLE was listed as a contributing cause of death, the leading underlying causes were heart disease (0.93), cancer (0.56), and COVID-19 (0.51). The overall age-adjusted SLE mortality rates were significantly higher in 2020 and 2021 than in all other study years, indicating the likely impact of the COVID-19 pandemic on SLE mortality.

Conclusion

Overall management of SLE, comorbidities, and infections in patients with SLE, as well as interventions targeting groups (eg, African American persons) disproportionately impacted by SLE, may reduce overall SLE mortality.

查看原文本刊更多论文

2018-2023年美国年龄≥15岁的系统性红斑狼疮患者死亡率

目的：系统性红斑狼疮（SLE）是一种可导致死亡的慢性自身免疫性疾病。为了检验SLE是否是潜在和促成死亡的原因，CDC分析了2018-2023年总体年龄≥15岁人群的死亡率数据，并按年龄、性别、种族和民族以及地区进行了分类。方法：使用CDC WONDER分析年龄≥15岁且提及SLE （ICD-10代码M32）的死亡证明数据。我们计算了年龄调整后的死亡率，并评估了性别、年龄、种族/民族和地区的模式。使用死因排序表和《国际疾病分类》分章节对潜在和促成死亡的原因进行了评估。结果：2018-2023年，14936例死亡在死亡证明上有SLE的记载。在这些死亡病例中，6414例（42.9%）将SLE列为潜在病因。年龄调整后的SLE死亡率，每百万人口中女性（5.97）高于男性（1.16），非西班牙裔非洲人（10.70）高于其他非西班牙裔种族群体（范围：2.46至5.62），西班牙裔与非西班牙裔（3.98对3.59），南方（4.37）高于其他地区。SLE被列为导致死亡的主要原因，主要的潜在原因是心脏病（0.93）、癌症（0.56）和COVID-19（0.51）。与所有其他研究年份相比，2020年和2021年的总体年龄调整SLE死亡率显着高于其他年份，这表明COVID-19大流行可能对SLE死亡率产生影响。结论：对SLE患者及其合并症和感染的全面管理，以及针对受SLE影响不成比例的人群（如非洲裔美国人）的干预措施，可能会降低SLE的总体死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis Care & Research RHEUMATOLOGY-

CiteScore

9.40

自引率

6.40%

发文量

368

审稿时长

3-6 weeks

期刊介绍： Arthritis Care & Research, an official journal of the American College of Rheumatology and the Association of Rheumatology Health Professionals (a division of the College), is a peer-reviewed publication that publishes original research, review articles, and editorials that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with rheumatic diseases, major topics are evidence-based practice studies, clinical problems, practice guidelines, educational, social, and public health issues, health economics, health care policy, and future trends in rheumatology practice.